Biomedical subjects
J F Godin
Publications and source records attributed to J F Godin.
[Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation].
This study was designed following the first documented case of torsades de pointes induced by sultopride hydrochloride, a substituted benzamide neuroleptic drug. The patient, a 48 year-old woman with no known cardiovascular disease, had been treated for several years with this drug. She was admitted for severe bronchospasm requiring artificial ventilation. Twenty-one hours after her admission, she developed several episodes of torsades de pointes, which were successfully treated with magnesium sulphate. At that time, the QT interval was 500 ms for a heart rate of 108 b.min-1 (QTc of 668 ms, and theoretical QTc 370 ms). On the fourth day, QTc was 548 ms and theoretical QTc 370 ms. The sultopride was stopped on the fifth day. Two days later, QTc was 397 ms. Six months later, there was no recurrence. Several cases of TdP or sudden death have been reported in patients receiving neuroleptic drugs. The effects of sultopride hydrochloride were therefore tested on isolated ferret Purkinje fibres, using the microelectrode technique. Three concentrations of the drug (D1, D2, D3) were tested, as well as normal Tyrode solution. Maximum diastolic potentials (Vmax) were -88.37 +/- 0.89 mV (control), -89.08 +/- 1.20 mV (D1), -90.00 +/- 1.06 mV (D2), and -90.14 +/- 1.20 mV (D3). Vmax was not affected by sultopride during pacing at 1,000 ms of cycle length. The duration of the action potential increased with the drug concentration. There was no early after-depolarisation (EAD) during control, and 7 out of 9 fibers had EAD and 3 out of 9 triggered activity in D3. The solvent (benzyl alcohol) did not modify the action potential.(ABSTRACT TRUNCATED AT 250 WORDS)
Warning from Biotec and Medtronic.
Explore the source record for details and available documents.
STIMAREC 1988 annual review.
Explore the source record for details and available documents.
STIMAREC report. Pacemaker failures due to electrocautery and external electric shock.
Explore the source record for details and available documents.
[Wolff-Parkinson-White syndrome. Value of transesophageal atrial stimulation coupled with exercise test for the study of anterograde conduction in the accessory pathway].
In patients with Wolff-Parkinson-White syndrome the anterograde conduction properties of the accessory pathway determine the ventricular rate in case of atrial fibrillation (AF). Anterograde conduction in the accessory pathway was evaluated in 20 patients (mean age 31 years) by means of transoesophageal atrial pacing with increasing frequency (up to 460 per minute), first at rest, then during exercise on an ergometric bicycle and upon immediate recovery. The exploration was completed by a search for the disappearance of pre-excitation during exercise and after an intravenous injection of ajmaline 1 mg/kg. The shortest cycle (SC) of atrial pacing with 1:1 conduction by the accessory pathway regularly decreased by 80 +/- 26 ms (n = 18), i.e. 27 p. 100 of its value at rest. At immediate recovery SC increased by 40 +/- 53 ms (n = 9). Atrial fibrillation was induced at rest and/or during exercise in 12 patients. The shortest interval (SI) between two pre-excited ventricular complexes was 290 +/- 80 ms (n = 8) at rest and 244 +/- 53 ms (n = 8) during exercise. With a substantial group of values (n = 12) there was good correlation between SC and SI both at rest and during exercise. With a smaller group of values (n = 3) SI was clearly greater than SC, suggesting a concealed conduction in the accessory pathway during atrial fibrillation. Disappearance of pre-excitation during exercise was observed in 4 patients, 3 of whom had a short (less than 250 ms) SC and/or SI.(ABSTRACT TRUNCATED AT 250 WORDS)
[Cardiac transplantation at the University Hospital Center of Nantes. 2 years' experience].
Between March, 1985 and April, 1987, 25 orthotopic heart transplantations were performed in 20 men and 5 women aged from 17 to 58 years (mean 42 years) on account of cardiomyopathy (n = 15), ischaemic heart disease (n = 6) or miscellaneous lesions (n = 4). The immunosuppressive treatment consisted of antilymphocyte serum and corticosteroids during 10 days; cyclosporine was introduced on the 7th day and continued thereafter in association with low-dose corticosteroid therapy. Endomyocardial biopsies were performed. Acute rejection, responsible for 2 deaths (one on the 10th day, the other in the 10th week), usually occurred within the first 3 months. Infections were frequent and often serious, resulting in one death in the 7th week. One out of patients had to be treated for arterial hypertension, and 3 patients presented with renal impairment (blood creatinine over 200 mumoles/l). The actuarial survival rate at 2 years is 84 p. 100. More than one-half of the patients have resumed social and occupational activities.
[Which pacemaker for which patient?].
Since the early 1980's, in parallel to development of "physiological" cardiac stimulation, modalities and objectives for cardiac stimulation have been modified radically. Among the many methods of stimulation available, in practice the physician may choose from four main types: (1) single-chamber ventricular stimulation; (2) single-chamber atrial stimulation; (3) two-chamber stimulation; (4) variable rate stimulation. Three main elements determine choice of the method of stimulation: the patient's physical condition, his heart condition (nature and type of cardiopathy and hemodynamic profile) and of course, electrophysiological data and cardiac rhythm encountered. The object of this paper is to schematically describe this choice.